文献速递心力衰竭与心肌病

SGLT2抑制剂优化实施与心力衰竭患者结局的关联

Association of Optimal Implementation of Sodium-Glucose Cotransporter 2 Inhibitor Therapy With Outcome for Patients With Heart Failure.
PubMed 文献 · JAMA Cardiol · 2020-01-01

IMPORTANCE: Sodium-glucose cotransporter 2 inhibitor (SGLT2-i) therapy provided incremental survival benefit to patients with heart failure and reduced ejection fraction (HFrEF) who received guideline-directed medical therapy regardless of type 2 diabetes status in a recent clini…

要点

  • 美国HFrEF患者中约69%为SGLT2-i治疗候选者。
  • 及时转化现有证据至实践可减轻HFrEF死亡负担。

核心结论

  • 优化实施SGLT2-i治疗可在美国预防大量死亡,支持及时将当前证据转化为实践以减轻HFrEF死亡负担。

临床怎么用

  • 对HFrEF患者应考虑优化实施SGLT2-i治疗以降低死亡风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Sodium-glucose cotransporter 2 inhibitor (SGLT2-i) therapy provided incremental survival benefit to patients with heart failure and reduced ejection fraction (HFrEF) who received guideline-directed medical therapy regardless of type 2 diabetes status in a recent clinical trial. To date, estimation of the potential benefits that could be gained from optimal implementation of SGLT2-i therapy at the population level has not been quantified. OBJECTIVE: To quantify the projected gains for deaths prevented or postponed with comprehensive implementation of SGLT2-i therapy for patients with HFrEF in the United States. DESIGN, SETTING, AND PARTICIPANTS: This decision analytical model, performed from September 25 to October 20, 2019, used published sources to estimate the US population of patients with HFrEF eligible for SGLT2-i therapy and the numbers needed to treat to prevent or postpone overt death. Sensitivity analyses were performed to account for the range of potential benefits. MAIN OUTCOMES AND MEASURES: All-cause mortality. RESULTS: Of the 3.1 million patients with HFrEF in the United States, 2 132 800 (69%) were projected to be candidates for SGLT2-i therapy. Optimal implementation of SGLT2-i therapy was empirically estimated to prevent up to 34 125 deaths per year (range 21 840-49 140 deaths per year). A secondary analysis excluding patients on the basis of N-terminal-pro brain natriuretic peptide levels and other trial entry criteria would yield a potential benefit of 25 594 deaths per year prevented (range, 16 380-36 855 deaths per year prevented). CONCLUSIONS AND RELEVANCE: This study suggests that a substantial number of deaths in the United States could be prevented by optimal implementation of SGLT2-i therapy. These data support implementation of the current evidence into practice in a timely manner to achieve important public health benefits and to reduce the mortality burden of HFrEF.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Bassi NS, Ziaeian B, Yancy CW, et al. Association of Optimal Implementation of Sodium-Glucose Cotransporter 2 Inhibitor Therapy With Outcome for Patients With Heart Failure. JAMA Cardiol. 2020. PMID: 32374344. doi:10.1001/jamacardio.2020.0898

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。